You save lives.

We help regain quality of life

Cancer survivors can face painful and function-limiting consequences as a result of their cancer and/or treatment.  The ReVital Cancer Rehabilitation Program was developed to help people affected by cancer prevent and/or restore their life roles, build strength, stamina, physical function and mobility; and maintain/regain independence. 

We Can Help

We understand the challenges oncologists face. Our solutions benefit your patients and you, their provider.

We help you improve Patient:

  • Satisfaction Scores

We give people affected by cancer the treatment and tools needed to decrease distress and improve their overall quality of life.

  • Care Pathway Compliance

Overwhelming fatigue, pain, numbness and tingling, and decreased functional ability are all potential side effects of cancer treatment. When these side effects become too burdensome, cancer treatment may be delayed or stopped. Cancer rehabilitation can potentially help by developing individualized programs with goals of maintaining or improving functional status, mobility, physical activity and decreasing pain and/or fatigue.

  • Reimbursement and Value-Based Scores

We help cancer survivors manage pain, balance, walking issues and excessive fatigue through individualized physical activity programs. This guidance can potentially decrease unnecessary emergency room visits, the risk of falls and office call-backs. 

Partnering with ReVital

A significant number of the 15.5 million people affected by cancer in the United States report lower long-term low physical quality of life than those without cancer.1,2,3 Preventing decline while restoring and maintaining function and quality of life is the primary mission of ReVital.

Whether you’re part of a small independent oncology practice or large hospital-based network, we seek to partner with oncology practices committed to high-quality care throughout the cancer journey.

We know your plate is full. That’s why we developed a simple referral process to provide your patients with the specialized care and support they need so you can focus on saving more lives. Not only will your patients appreciate the opportunity to engage in their own care, your team will benefit by partnering with a rehabilitation provider dedicated to cancer care.


Occupational Therapy
Satisfaction

The ReVital team understands the everyday difficulties that individuals affected by cancer face. We work collaboratively with oncology partners to develop a tailored evidence-based  program that provides a positive impact. Often, by treating distressing physical issues with our hands-on, individualized approach, other psychosocial impacts of cancer can also be mitigated.

Operational Efficiency
Operational Efficiency 

We work as a team with oncology care members to easily and effectively integrate services and overall treatment. Integrated care has been shown to improve satisfaction4 and outcomes and decrease cost.5

Value Based Care
Aligned to Value-Based Care

Evidence shows that individuals with cancer who have numbness and tingling (peripheral neuropathy) have a three times greater chance of falling.6 Pain and fatigue are two primary reported reasons for community-dwelling adults with cancer to have unplanned visits and hospitalizations.7 Prevention of falling, extreme fatigue and pain are potentially modifiable by cancer rehabilitation. ReVital seeks to proactively address these issues, among others (functional decline, decreased endurance, etc.), that can impact quality of life, individual costs and overall alternative payment models.

Quality
Quality

Cancer treatment compliance is a major area of focus for most of our oncology partners. By tracking patient-reported and objective outcome measures, we help people affected by cancer prepare for changes in their active treatment. A decline in functional status, a limited ability to walk one block or more, the need for assistance in taking medications, decreased social activities and falling can predict chemotherapy toxicity.8 Our ReVital therapists help individuals maintain strength and function; engagement in activity and prevent fall risk, while adopting self-management strategies to address pain, fatigue and distress so they can maintain the prescribed regimen.

Certified Clinicians
Certified Clinicians

Our commitment is not only to be the largest cancer rehabilitation program – we are also dedicated to being the best.  Our clinicians must undergo extensive training to be certified in the ReVital program.  Training can include hundreds of hours of didactic, hands-on workshops, and group learning sessions.  

Resources

  1. Weaver KE, Forsythe LP, Reeve BB, et al. Mental and Physical Health–Related Quality of Life among U.S. Cancer Survivors: Population Estimates from the 2010 National Health Interview Survey. Cancer Epidemiology Biomarkers & Prevention.
  2. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016;66(4):271-289.
  3. Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health‐related quality of life in older adult survivors of selected cancers: Data from the SEER‐MHOS linkage. Cancer. 2015;121(5):758-765.
  4. Joseph SC, Barnard S, Macduff C, Moffat M, Walker P, Diack L. Users' perceptions of interprofessional collaborative care during their cancer journeys'. 201
  5. Mittmann N, Beglaryan H, Liu N, et al. Examination of Health System Resources and Costs Associated With Transitioning Cancer Survivors to Primary Care: A Propensity-Score–Matched Cohort Study. Journal of Oncology Practice. 2018:JOP.18.00275.
  6. Kolb NA, Smith AG, Singleton JR, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA neurology. 2016;73(7):860-866.
  7. Aprile G, Pisa F, Follador A, et al. Unplanned presentations of cancer outpatients: a retrospective cohort study. Supportive Care in Cancer. 2013;21(2):397-404.
  8. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Journal of Clinical Oncology. 2011;29(25):3457.